Drug Approval | January 24, 2023
USFDA inspection at Indoco Remedies's Solid Oral Formulation Facility at Goa
USFDA issued issued Form 483 with nine observations, which will be addressed within stipulated time.
USFDA issued issued Form 483 with nine observations, which will be addressed within stipulated time.
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
The company will respond to these observations within the stipulated time period.
The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.
ANSSI Wellness launches Asia’s premier and USA-patented ‘Spinal Decompression Treatment’ center in Nashik
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
The new facility will be able to handle four times as many patients as the previous facility.
There have been reports from Uzbekistan concerning contaminated cough syrup Dok1 Max made by Indian company Marion Biotech, Noida, Uttar Pradesh
Subscribe To Our Newsletter & Stay Updated
